BWXT Poised For Best-In-Class Results: Analyst Foresees Growth From Microreactors And High-Margin Medical Rev
Portfolio Pulse from Nabaparna Bhattacharya
Truist Securities analyst Michael Ciarmoli has reiterated a Buy rating on BWX Technologies, Inc. (BWXT), raising the price target to $83 from $77. Ciarmoli believes that BWXT's numerous revenue growth drivers, monopolistic market positions, and a resurgence in the commercial nuclear market will enable it to post best-in-class results among its peers over the next 12-36 months. The analyst also sees signs of microreactor adoption in the commercial market and anticipates that the high-margin medical rev growth acceleration will complement stability in the company's core naval defense market.
August 14, 2023 | 7:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BWX Technologies, Inc. (BWXT) has received a reiterated Buy rating from Truist Securities analyst Michael Ciarmoli, who has raised the price target to $83 from $77. Ciarmoli anticipates best-in-class results for BWXT over the next 12-36 months due to its numerous revenue growth drivers and a resurgence in the commercial nuclear market.
The analyst's positive outlook on BWXT, including the raised price target and the anticipation of best-in-class results, is likely to instill confidence in investors and could drive the stock price up in the short term. The company's numerous revenue growth drivers and the resurgence in the commercial nuclear market are seen as strong positives.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100